Compare Stocks: ABVC, PYPD, ICCC, and VRCA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$0.89 -5.0%	$1.26	$0.82 ▼ $3.40	$24.96M	0.57	104,407 shs	97,751 shs
ICCC ImmuCell	$10.09 -0.4%	$10.52	$4.52 ▼ $12.10	$92M	0.54	28,909 shs	83,716 shs
PYPD PolyPid	$5.08 +1.4%	$4.77	$3.06 ▼ $5.73	$95.61M	1.41	181,278 shs	129,448 shs
VRCA Verrica Pharmaceuticals	$4.86 -2.6%	$5.61	$3.28 ▼ $9.82	$85.72M	1.49	57,979 shs	138,117 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-4.97%	-7.24%	-27.65%	-21.94%	-71.20%
ICCC ImmuCell	-0.39%	-7.43%	-9.83%	-0.30%	+67.19%
PYPD PolyPid	+1.40%	+6.28%	+35.83%	+1.20%	+45.14%
VRCA Verrica Pharmaceuticals	-2.61%	0.00%	-10.66%	-19.80%	-12.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$0.89 -5.0%	$1.26	$0.82 ▼ $3.40	$24.96M	0.57	104,407 shs	97,751 shs
ICCC ImmuCell	$10.09 -0.4%	$10.52	$4.52 ▼ $12.10	$92M	0.54	28,909 shs	83,716 shs
PYPD PolyPid	$5.08 +1.4%	$4.77	$3.06 ▼ $5.73	$95.61M	1.41	181,278 shs	129,448 shs
VRCA Verrica Pharmaceuticals	$4.86 -2.6%	$5.61	$3.28 ▼ $9.82	$85.72M	1.49	57,979 shs	138,117 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-4.97%	-7.24%	-27.65%	-21.94%	-71.20%
ICCC ImmuCell	-0.39%	-7.43%	-9.83%	-0.30%	+67.19%
PYPD PolyPid	+1.40%	+6.28%	+35.83%	+1.20%	+45.14%
VRCA Verrica Pharmaceuticals	-2.61%	0.00%	-10.66%	-19.80%	-12.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
ICCC ImmuCell	2.00	Hold	N/A	N/A
PYPD PolyPid	2.50	Moderate Buy	$11.33	123.10% Upside
VRCA Verrica Pharmaceuticals	2.25	Hold	$14.50	198.35% Upside

Current Analyst Ratings Breakdown

Latest ABVC, PYPD, ICCC, and VRCA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
7/22/2026	PYPD PolyPid	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
7/21/2026	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
7/15/2026	VRCA Verrica Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/2/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	PYPD PolyPid	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/29/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/26/2026	VRCA Verrica Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	$0.46 per share	N/A
ICCC ImmuCell	$27.64M	3.31	$0.19 per share	52.54	$3.45 per share	2.92
PYPD PolyPid	N/A	N/A	N/A	N/A	$0.28 per share	N/A
VRCA Verrica Pharmaceuticals	$35.58M	2.35	N/A	N/A	$0.25 per share	19.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.30	N/A	N/A	N/A	N/A	-47.68%	-30.97%	N/A
ICCC ImmuCell	-$1.04M	$0.08	126.14	N/A	N/A	2.57%	2.69%	1.76%	N/A
PYPD PolyPid	-$34.17M	-$1.48	N/A	N/A	N/A	N/A	-311.08%	-150.83%	N/A
VRCA Verrica Pharmaceuticals	-$17.89M	-$1.67	N/A	N/A	N/A	-102.84%	-407.11%	-70.17%	N/A

Latest ABVC, PYPD, ICCC, and VRCA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ICCC ImmuCell	$0.05	$0.20	+$0.15	$0.20	$5.40 million	$7.19 million
8/12/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	-$0.03	+$0.37	-$0.03	$0.11 million	N/A
8/12/2026	Q2 2026	PYPD PolyPid	-$0.3775	-$0.35	+$0.0275	-$0.35	$0.30 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A
PYPD PolyPid	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.07	0.07
ICCC ImmuCell	0.22	4.75	2.71
PYPD PolyPid	N/A	1.35	1.35
VRCA Verrica Pharmaceuticals	0.18	1.45	1.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ICCC ImmuCell	13.47%
PYPD PolyPid	26.47%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
ICCC ImmuCell	5.70%
PYPD PolyPid	24.70%
VRCA Verrica Pharmaceuticals	52.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	26.65 million	21.59 million	Not Optionable
ICCC ImmuCell	70	9.08 million	8.56 million	Not Optionable
PYPD PolyPid	80	19.08 million	14.37 million	No Data
VRCA Verrica Pharmaceuticals	40	17.18 million	8.09 million	No Data

ABVC, PYPD, ICCC, and VRCA Headlines

Recent News About These Companies

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts

August 20 at 4:13 AM | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Buys 4,200 Shares

August 19 at 6:36 AM | insidertrades.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

August 18 at 5:21 PM | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares

August 18 at 5:21 PM | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Wall Street Zen to Strong Sell

August 15, 2026 | americanbankingnews.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

August 15, 2026 | marketbeat.com

Verrica (VRCA) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Verrica Pharmaceuticals Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results

August 6, 2026 | marketbeat.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 6, 2026 | manilatimes.netM

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

August 6, 2026 | finance.yahoo.com

Verrica Pharmaceuticals (VRCA) Projected to Release Quarterly Earnings on Thursday

August 2, 2026 | marketbeat.com

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Recommendation of "Hold" by Brokerages

July 26, 2026 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to Sell at Wall Street Zen

July 25, 2026 | marketbeat.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum ...

July 21, 2026 | markets.businessinsider.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

July 21, 2026 | globenewswire.com

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment ...

June 23, 2026 | markets.businessinsider.com

Verrica Pharmaceuticals Announces First U.S. and Japanese Patients Dosed in Phase 3 COVE-3 Trial of YCANTH for Common Warts

June 22, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC, PYPD, ICCC, and VRCA Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$0.89 -0.05 (-4.97%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$0.89 +0.00 (+0.01%)

As of 04:00 AM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

ImmuCell NASDAQ:ICCC

$10.09 -0.04 (-0.39%)

As of 08/20/2026 04:00 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

PolyPid NASDAQ:PYPD

$5.08 +0.07 (+1.40%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$5.08 +0.00 (+0.08%)

As of 04:01 AM Eastern

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Verrica Pharmaceuticals NASDAQ:VRCA

$4.86 -0.13 (-2.61%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$4.86 0.00 (-0.08%)

As of 08/20/2026 05:41 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABVC, PYPD, ICCC, and VRCA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABVC, PYPD, ICCC, and VRCA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABVC, PYPD, ICCC, and VRCA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC, PYPD, ICCC, and VRCA Company Descriptions

ABVC BioPharma NASDAQ:ABVC

ImmuCell NASDAQ:ICCC

PolyPid NASDAQ:PYPD

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABVC, PYPD, ICCC, and VRCA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABVC, PYPD, ICCC, and VRCA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABVC, PYPD, ICCC, and VRCA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC, PYPD, ICCC, and VRCA Company Descriptions

ABVC BioPharma NASDAQ:ABVC

ImmuCell NASDAQ:ICCC

PolyPid NASDAQ:PYPD

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools